Excitotoxicity is well known in the neuronal death in the brain and is also linked to neuronal damages in the retina. Recent accumulating evidence show that microglia greatly affect excitotoxicity in the brain, but their roles in retina have received only limited attention. Here, we report that retinal excitotoxicity is mediated by microglia. To this end, we employed three discrete methods, that is, pharmacological inhibition of microglia by minocycline, pharmacological ablation by an antagonist for colony stimulating factor 1 receptor (PLX5622), and genetic ablation of microglia using Iba1-tTA::DTA tetO/tetO mice. Intravitreal injection of NMDA increased the number of apoptotic retinal ganglion cells (RGCs) followed by reduction in the number of RGCs.
diseases (Kalia, Kalia, & Salter, 2008) . Excitotoxicity-induced neuronal death was identified more than 50 years ago (Lucas & Newhouse, 1957) , and ionotropic glutamate receptors, including N-methyl-Daspartate (NMDA), have been suggested to be key molecules that evoke neuronal damage (Choi, 1992; Dirnagl, Iadecola, & Moskowitz, 1999; Lee, Zipfel, & Choi, 1999) . In addition to neurons in the brain, NMDA has long been used to induce excitotoxicity of retinal ganglion cells (RGCs) in vivo (Li, Schlamp, & Nickells, 1999; Siliprandi et al., 1992) .
RGCs sprout their axons to the brain thereby transmitting visual information from the retina to the brain, thus degeneration of RGCs is a primal cause of blindness in various ocular injuries and diseases. Previous studies have shown that excitotoxicity contributes to the death of RGCs and other retinal neurons in various ocular injuries and diseases including diabetic retinopathy (Simo, Hernandez,, & European Consortium for the Early Treatment of Diabetic, 2014), oxygenglucose deprivation (Romano, Price, Almli, & Olney, 1998) , retinal ischemia (Adachi et al., 1998) , retinal detachment (Diederen et al., 2006; Sherry & Townes-Anderson, 2000) , retinitis pigmentosa (Delyfer et al., 2005) and experimental autoimmune optic neuritis (Suhs et al., 2014) . In addition, glutamate-mediated excitotoxicity has been proposed to underlie RGC damages in rodent and primate model of glaucoma (Casson, 2006; Hare et al., 2001; Hare et al., 2004; Seki & Lipton, 2008) . Supporting these reports, pharmacological inhibition of excitatory amino acid transporters (Vorwerk et al., 2000) or selective knockout of glutamate aspartate transporter or excitatory amino acid carrier 1 (Harada et al., 2007) , causes RGC degeneration spontane- we focused on glial cell-mediated non-cell-autonomous mechanism of RGC damages because many reports have shown that glial cells enhance the damages of RGCs (Lebrun-Julien et al., 2009; Ullian et al., 2004) .
Among glial cells, microglia are the one of the most probable candidates participating in this process. For example, damages of spinal cord neurons evoked by NMDA were much enhanced in the presence of microglia (Tikka, Fiebich, Goldsteins, Keinanen, & Koistinaho, 2001; . Similarly, microglia-enhanced damage of cerebellar granule cells has been reported (Kim & Ko, 1998) . Minocycline (MC), widely used as an inhibitor for microglia, significantly protects neurons against exitotoxicity. MC has also been demonstrated to suppress microglial activation and protect RGCs in various models including optic nerve crush/transection (Baptiste et al., 2005;  Levkovitch-Verbin, Kalev-Landoy, Habot-Wilner, & Melamed, 2006) , ocular hypertension (Levkovitch-Verbin et al., 2006) , diabetes (Krady et al., 2005) , branch retinal vein occlusion (Sun, Li, He, Zhang, & Tao, 2013) , experimental autoimmune encephalomyelitis (Maier et al., 2007) and glaucoma (Bosco et al., 2008) . Although many reports
showed that reactive microglia have neurotoxic roles in the retina, there is no report showing microglial involvement in the NMDAevoked RGC damages, mainly because microglia do not express functional NMDA receptors.
In this study, we demonstrate that activated microglia are essential for the NMDA-induced degeneration of RGCs, suggesting a critical role of microglia-mediated non-cell-autonomous mechanisms for degeneration of RGCs evoked by excitotoxic insults.
| MATERIALS AND METHODS

| Animals
All animals used in this study were obtained, housed, cared for and used in accordance with the "Guiding Principles in the Care and Use of Animals in the Field of Physiologic Sciences" published by the Physiologic Society of Japan, and with the previous approval of the Animal Care Committee of Yamanashi University (Chuo, Yamanashi, Japan).
Wild-type male mice (C57BL/6, 3-months old) were obtained from Japan SLC (Shizuoka, Japan).
| Chemicals and antibodies
Reagents were obtained from the following sources. Anti-Iba1 antibody Brain-derived neurotrophic factor (BDNF, 450-02) and ciliary neurotrophic factor (CNTF, were purchased from Peprotec Inc.
(Rockey Hill, NJ). Bovine serum albumin (BSA), cytidine-5 0 -dishosphocholine sodium dihydrate, L-cystein, forskolin, hydrocortisone, insulin, MC, NMDA, progesterone, selenite, transferrin and triton X-100 were purchased from Sigma-Aldrich (St. Louis, MO 
| Primary mouse RGC culture
We prepared the RGC culture as previously reported (Taguchi et al., 2015) . Briefly, retinae were removed from eyes of neonatal mice (P0) and digested in Ca 2+ /Mg 2+ -free HBSS containing 5 mg/mL of papain, 0.24 mg/mL of L-cysteine and 5 μM of EDTA for 20 min at 37 C with gentle agitation. The tissues were centrifuged at 800 × g for 5 min followed by suspension in BSA solution (0.5% BSA and 0.04% DNase I in HBSS) and trituration 20 times. Müller cells (Taguchi et al., 2015) .
| Primary mouse retinal microglia culture
Primary retinal microglia were prepared as previously reported (Roque & Caldwell, 1993 -free HBSS containing 0.025% trypsin-EDTA for 15 min at 37 C with gentle agitation. Cell suspension was added with 1/10 volume of horse serum and centrifuged at 1000 × g for 10 min. Supernatants were discarded and the cells were resuspended and incubated in DMEM (11965-092) supplemented with 10% fetal bovine serum, 100 U/mL of penicillin and 100 μg/mL of streptomycin at 37 C under 10% CO 2 and maintained with medium change every few days. A few weeks after plating, microglia were collected by gentle shaking at 100 rpm for 1 min. Microglial morphologies were clearly distinct from RGCs and the culture contained no RGCs.
| Sholl analysis of microglia
Morphologies of microglia were analyzed by Sholl analysis (Sholl, 1953) . We used Fiji software (https://fiji.sc/). Briefly, fluorescent images were converted into black and white (binary) images by Image > Type > 8 bit followed by converting fluorescent signals to black color by Edit > Invert. After adjusting the threshold by Image > Adjust > Threshold, an ending radius for the analysis was set using the "Straight" drawing tool from the menu. We then ran the Sholl analysis by Analyze > Sholl > Sholl analysis.
| Ca 2+ imaging
Ca 2+ imaging of primary cells was performed by the fura 2 method as previously reported (Shinozaki et al., 2014; Taguchi et al., 2015) . In brief, the culture medium was replaced with balanced salt solution (BSS) composed of (in mM): NaCl 150, KCl 5.0, CaCl 2 1.8, MgCl 2 1.2, HEPES 25, and D-glucose 10 (pH 7.4). Cells were loaded with 10 μM fura 2-acetoxymethyl ester (fura 2-AM) at room temperature in BSS for 45 min. After loading, the samples were mounted on a microscope (ECLIPSE TE2000-U, Nikon, Tokyo, Japan) equipped with a 75-W xenon lamp and band-pass filters of 340 and 380 nm for measurement of the Ca
2+
-dependent signals (F340 and F380 nm). Image data were recorded by a CCD camera (ORCA-ER, Hamamatsu Photonics, Shizuoka, Japan). For evaluation, we used the ratio of F340/F380.
| Serial block-face scanning electron microscopy
Enucleated eyes were immersed in 0.1 M PB (pH 7.4) containing 4%
PFA (163-25983, Wako) and 0.5% glutaraldehyde (077-06271, Wako) for 3 hr at room temperature. The hemisphere including the cornea and ciliary body were cut off, and the remaining parts were further fixed for 12 h at 4 C. The eyes with attached optic nerves were post-fixed and stained with reduced OsO 4 , thiocarbohydrazide, OsO 4 and lead aspartate, and embedded in conductive resin, as described previously Shinozaki et al., 2017a; Thai et al., 2016 
| Intravitreal NMDA injection
We performed NMDA-evoked excitotoxicity in the eye as previously reported (Li et al., 1999) . Mice were anesthetized with intraperitoneal injection of a mixture of medetomidine hydrochloride (0.3 mg/kg), midazolam (4 mg/kg) and butorphanol tartrate (5 mg/kg), followed by instillation of 0.5% bupivacain (5 μL/eye). Then, a small incision was made with a 30-gauge needle 0.5-1.0 mm behind the limbus in the superior region of the globe of the eye. NMDA (2 μL at 10 mM in saline) was injected into the eyes using a glass capillary with a 40-50 μm diameter opening size. Naïve mice were used as control groups.
Sham operation was performed by injecting vehicle (2 μL of saline), and the absence of RGC degeneration or microglial activation was confirmed. To estimate the NMDA-caused damages of RGCs, we quantified the changes in the number of Brn3a + RGCs in the ganglion cell layer (GCL) of the retina.
| Instillation of MC
MC (100 μM in saline, pH 7.4), an inhibitor of microglial activation (Yrjanheikki, Keinanen, Pellikka, Hokfelt, & Koistinaho, 1998) , was instillated at a volume of 5 μL/eye. Eye drops of MC were administered once or twice a day from 3 days before to 7 days after NMDA injection ( Figure 3a ).
| Pharmacological ablation of microglia
PLX5622 (PLX), a selective antagonist for colony stimulating factor recptor 1 (CSF1R) was provided under MTA by Plexxikon Inc.
(Berkley, CA). PLX3379 (Elmore et al., 2014) and PLX significantly reduce microglial number in the brain (Acharya et al., 2016) . To deplete retinal microlia, mice received a PLX-containing diet (1,200 ppm) from 7 days before to 7 days after the NMDA injection. AIN-76A, a chow diet containing the same composition other than PLX, was used for control groups.
| Genetic ablation of microglia
For genetic ablation of microglia, we overexpressed diphtheria toxin (DTA) in microglia by crossing Iba1-tTA (Tanaka et al., 2012 ) and tetO-DTA mice (Stanger, Tanaka, & Melton, 2007 (Figure 5c ), which is a higher efficiency than the previous study in the cerebral cortex (Miyamoto et al., 2016 (Shinozaki et al., 2017b) . Retinae were removed from enucleated eyes and eight retinae were digested in 1,900 μL of buffer Z containing buffer Y (20 μL), enzyme A (10 μL), and P (50 μL) using the dissociation program of the tube rotator. A 20 mL of ice-cold PBS containing 0.5% (wt/vol) BSA (PBS/BSA) were added, mixed, and samples filtered with a cell strainer (100 μL). Samples were centrifuged at 300 × g for 7 min at 4 C and the supernatant discarded. The pellet was resuspended in 3100 μL of PBS/BSA and 900 μL of debris removal solution (130-109-398) added followed by 4 mL PBS/BSA and centrifugation at 3,000 × g for 10 min at 4 C. The supernatant was aspirated and 15 mL of PBS/BSA added and mixed well. Samples were centrifuged at 300 g for 7 min at 4 C and the supernatant discarded. An 80 μL of PBS/BSA and 10 μL of FcR blocking buffer were then added followed by 10 μL of anti-CD11b microbeads (130-093-636). Samples were incubated for 15 min at 4 C, centrifuged at 300 × g for 7 min at 4 C, and the cells resuspended in 500 μL PBS/BSA. The cells were then transferred to an LS column (130-042-401). The column was then set on a magnetic stand and 3 mL PBS/BSA added three times.
The column was then removed from the magnet and 3 mL PBS/BSA added. The flow through was collected as the CD11b-negative (CD11b − ) fraction. Another 3 mL of PBS/BSA was then added to the column and the fraction containing the anti-CD11b-attached retinal microglia was collected. Using this technique, the CD11b-positive fraction express Emr1, Tyrobp, Itgam, Aif1 and Cxcr1 genes (Supporting Information Figure S2a ) but not genes for RGC maker such as Pou4f1 and Sncg genes (Supporting Information Figure S2b ).
In contrast, CD11b − fraction express Pou4f1 and Sncg but not Emr1, Tyrobp, Itgam, Aif1 and Cxcr1 genes, indicating successful purification of microglia from retina.
| Blocking of tumor necrosis factor-α signaling
To prevent NMDA-induced tumor necrosis factor α (TNFα) signaling, we used two alternative methods: a selective inhibitor for TNFα and siRNA for TNF receptors 1 and 2. For pharmacological inhibition of TNFα, we used SPD-304 (SPD). SPD has been shown to prevent formation of the functional homotrimeric structure of TNFα (He et al., 2005) . SPD (1 μL at 20 mM in saline) was injected simultaneously with NMDA (1 μL at 20 mM in saline). Total injection volume and final concentration of NMDA were the same as the NMDA alone condition.
in vivo siRNA experiments were performed as previously reported (Turchinovich, Zoidl, & Dermietzel, 2010) . Briefly, 1 μL of siRNA 
| Immunohistochemistry
Mice were anesthetized with a mixture of medetomidine hydrochloride (0.3 mg/kg), midazolam (4 mg/kg) and butorphanol tartrate (5 mg/kg) (i.p.). Preparation for whole-mounted retinae was performed as previously reported (Shinozaki, Kashiwagi, et al., 2017a) . Eyes enucleated from mice were further fixed for 24 hr in 4% PFA at 4 C. The retinae removed from eyes were blocked with 2% goat serum and 0.5 M NaCl in 2% triton X-100-containing PBS (PBST) for 1 hr at room temperature. Then, samples were incubated with primary antibodies anti-rabbit IgG (1:1,000, Thermo Fisher Scientific) were used. Primary and secondary antibodies were diluted in 2% goat serum-containing PBST and PBS, respectively. Nuclei were stained with DAPI (1:1,000, DOJINDO, D523). Fluorescent images were acquired within 500 μm of the optic nerve head (white squares indicated in Figure 1a ) using FV1000 laser scanning confocal microscope (Olympus, Tokyo, Japan).
Images for counting RGC number were also obtained from 4 area/retina and the data were averaged because the injected NMDA may be diffused irregularly in the vitreous chamber.
| Quantitative PCR
Total RNA was isolated and purified from retinae using RNAiso Plus (9108, Takara Bio Inc.) according to the manufacturer's instructions. Reverse transcription was performed at 37 C for 15 min followed by inactivation at 85 C for 5 s using Primescript RT reagent Kit (RR037A, Takara Bio Inc.).
The reaction mix contained 10 ng of cDNA, 5 pmol of probes, 10 pmol of primers and PrimeTime Gene Expression Master Mix. PCR amplification and real-time detection were performed using an Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, CA). For PCR reaction, activation of polymerase was performed at 95 C for 3 min; the temperature profile consisted of 40 cycles of denaturation at 95 C for 15 s and annealing/extension at 60 C for 1 min. The primers and probes for mouse (Supporting Information Figure S2a ). This fraction expressed no RGCenriched genes such as Pou4f1 and Sncg (Supporting Information Figure S2b ). In contrast, CD11b-negative fraction expressed RGCenriched genes but not microglia-enriched genes. CD11b + fraction expressed no NMDA receptor genes including Grin1, Grin2a, Grin2b, Grin2c, Grin2d, Grin 3a, or Grin 3b whereas negative fraction expressed Grin1, Grin2a-2d and Grin3a but not Grin 3b (Supporting Information Figure S2c ), corresponding to the previous studies (Brandstatter, Koulen, & Wassle, 1998; Hartveit et al., 1994; Prybylowski & Wenthold, 2004; Shen, Liu, & Yang, 2006; Vandenbranden, Kamphuis, Nunes Cardozo, & Kamermans, 2000) . Our data show that functional NMDA receptors are expressed in RGCs but not in microglia, and that NMDA causes degeneration of RGCs and activation of microglia.
| Microglial activation occurs accompanying RGC degeneration
We next investigated temporal patterns of microglial activation and RGC degeneration induced by NMDA. No changes in the number of Brn3a + RGCs were observed at 12 hr or D1, whereas a time-dependent reduction of RGCs was observed from D3 to D7 (Figure 2a,c) . Microglial number was slightly, but significantly, increased at D1, which peaked at D3 followed by a slight reduction at D7 (Figure 2b,d ).
Because microglia change their morphologies in response to extracellular stimuli, we then examined microglial morphologies after NMDA injection using Sholl analysis. Microglia retracted their processes as early as 12-hr post-injection (Figure 2e ). At D3, many microglia exhibited bipolar shapes with their two long processes oriented to the optic nerve head and to the periphery. These temporal patterns of microglia and RGCs indicate that microglial activation after NMDA injection associated with RGC degeneration. 
| Pharmacological inhibition of microglia protects RGCs against NMDA-induced excitotoxicity
To clarify whether activated microglia induces RGC degeneration in the NMDA injection model, we pharmacologically inhibited microglia using MC, a semisynthetic tetracycline antibiotic. We performed daily instillation of MC (100 μM, 5 μL) from 3 days before to 7 days after NMDA injection (Figure 3a) . Without MC, NMDA reduced RGCs by about 70% at D7 (Figure 3b ). MC significantly restored the NMDAinduced reduction in RGC number. In contrast, the number of microglia was increased at D7, and MC suppressed the NMDA-induced increase in microglial number (Figure 3c ). MC also suppressed the retracted processes and hypertrophic cell bodies of the microglia (see also Figure 7b ). These data indicate that reactive microglia are one cause of RGC damage induced by NMDA.
| Pharmacological ablation of microglia protects RGCs
As MC has also been reported to have other effects, including antioxidative properties (Shimazawa, Yamashima, Agarwal, & Hara, 2005) , we used an alternative method to better understand the role of microglia in RGC degeneration. We examined an antagonist for CSF1R, which has been demonstrated to eliminate more than 90% of microglia in the brain after 7-day application (Elmore et al., 2014) . In our condition, mice received CSF1R antagonist PLX5622 (PLX, 1200 ppm) from 7 days before to 7 days after saline treatment (Figure 4a ), which exhibited a partial, but significant, protective effect on RGCs FIGURE 2 Microglial activation occurs before RGC degeneration. Whole-mount retinae were labeled with antibodies against (a) Brn3a (RGC marker) and (b) Iba1 (microglia marker). Microglia showed dramatic morphological changes (e.g., retracted processes) at 12 hr postinjection, and they exhibited a bipolar shape associated with RGC axons at D3 and D7. Enlarged images show representative morphologies of microglia at each time point. (c) rgc number was significantly decreased from D3 to D7 after NMDA injection. No changes were observed at 12 h and D1 (n = 3-6, **p < .01 versus. control, one-way ANOVA followed by Fisher's LSD test). (d) Microglia showed a slight, but significant, increase in their cell number as early as D1, and peaked at D3 (n = 3-6, **p < .01 vs. control, one-way ANOVA followed by Fisher's LSD test). (e) Sholl analysis of morphological changes in microglia. At 12 hr, microglia showed significant process retraction. At D3-7, microglial cell bodies and processes got thicker and showed a bipolar shape associated with an axon. Scale bars: 100 μm and 25 μm in (a) and (b) [Color figure can be viewed at wileyonlinelibrary.com] (Figure 4c ), similar to the previous report (Ebneter, Kokona, Jovanovic, & Zinkernagel, 2017) . In our condition, PLX did not change the number of RGCs in the absence of NMDA. NMDA dramatically increased microglial number in AIN-treated mice but not in PLXtreated mice.
As described earlier, because MC may have direct neuroprotective potentials (Moller et al., 2016; Shimazawa et al., 2005) , we further evaluated microglia-independent effect by MC. MC treatment in the presence of PLX showed almost no microglia at D7 (Figure 4c ). Under this condition, MC plus PLX showed higher protective effect on RGCs than that by PLX only (Figure 4b ).
| Genetic ablation of microglia protects RGCs against NMDA-induced excitotoxicity
Because CSF1R expression is not restricted to microglia and is expressed in other cell types, we employed an alternative method. To further confirm the neurotoxic role of activated microglia, we selectively ablated microglia using Iba1-tTA::DTA tetO/tetO (Iba1-DTA) mice (Miyamoto et al., 2016) (Figure 5a ). In the presence of DOX, microglia in the transgenic mice were normal and microglial number was not different from that in wild-type mice (data not shown). When DOX is withdrawn (DOX-Off ), DTA is overexpressed selectively in Iba1 + cells.
Two weeks after DOX-Off, the NMDA-induced reduction in RGC number was slightly but significantly restored (Figure 5b ). Under this condition, about 90% of microglia disappeared in the control conditions ( Figure 5c ), a higher ablation rate than that in the cerebral cortex (about 50%) (Miyamoto et al., 2016) . Ablation of microglia did not affect RGC number in the absence of NMDA. These results from MC, PLX and Iba1-DTA indicate that microglia have a neurotoxic effect after the intravitreal NMDA injection.
We unexpectedly found that microglial number dramatically increased even though they are almost completely abated in the absence of NMDA (Figure 5c ). The majority of microglia (>80%) at D1 was co-labeled with Ki67, a marker for cell proliferation (Supporting Information Figure S3 ). We did not see Ki67 + microglia at D7 (data not shown), so we defined D1 and D3 as repopulation phase of microglia and examined their phenotypes by checking several markers. Although the hypothesis for M1/M2 microglial polarization is under debate (Ransohoff, 2016) , the molecular markers for M1/M2 phenotypes seem to be closely correlated to neurotoxic/ neuroprotective phenotypes of microglia. We used iNOS and CD68
to profile neurotoxic properties of microglia (Mander & Brown, 2005; Papageorgiou et al., 2016) and arginase-1 (Arg1) and CD206
for neuroprotective or antiinflammatory microglia (Lee et al., 2002; Ma et al., 2010) . During repopulation, microglia showed similar amount of neurotoxic (iNOS and CD68) (Supporting Information Figure S4 ) and neuroprotective (Arg1 and CD206) markers (Supporting Information Figure S5 ). These data show that repopulating microglia have no polarization toward neurotoxic or neuroprotective phenotype. MC protects RGCs against NMDA-induced excitotoxicity (a) the experimental schedule for MC treatment. MC (MC, 100 μM, 5 μL/ eye) was topically applied every day to the eyes of mice. MC was administered from 3 days before to 7 days after NMDA injection. (b) NMDAinduced reduction in RGC number at D7 was significantly attenuated by MC (n = 3-6, **p < .01 vs. control, ## p < .01 vs. NMDA, one-way ANOVA followed by Fisher's LSD test). (c) Microglial activation was also inhibited by MC. Microglia showed ramified shape in controls, whereas they showed increased Iba1 immunoreactivity and cell number upon stimulation with NMDA (D7). MC clearly reversed NMDA-induced morphological changes to similar to those in control conditions. The number of microglia increased by NMDA injection, which was attenuated by MC (n = 3-6, **p < .01 vs. control, ## p < .01 vs. NMDA, one-way ANOVA followed by Fisher's LSD test) [Color figure can be viewed at wileyonlinelibrary.com]
| Microglia upregulate TNFα expression in response to NMDA injection
To clarify molecular mechanisms involved in the neurotoxic effects of microglia, we analyzed temporal patterns of genes related to inflammatory responses. Because proinflammatory cytokines, including TNFα, interleukin-1β (IL-1β) and -6 (IL-6) have been reported to be increased in the aqueous humor of primary open-angle glaucoma (POAG) patients (Balaiya, Edwards, Tillis, Khetpal, & Chalam, 2011; Markiewicz et al., 2015; Ohira et al., 2015; Sawada, Fukuchi, Tanaka, & Abe, 2010) , we investigated retinal expression of Tnfα, Il-1β, and Il-6 mRNAs and found that all of them were significantly upregulated at D1 (500-, 60-and 40-fold increases, respectively; Figure 6a-c) . Similarly, Aif1 mRNA, a marker for microglia, was significantly upregulated at D1 (Figure 6d ). To test if these cytokine expressions were controlled by microglia, we inhibited microglial activation using MC. Notably, MC showed dramatic suppression selectively on Tnfα mRNA, but only a slight effect on Il6 and no effect on Ilb (Figure 6e-g ). Proinflammatory cytokine genes are upregulated after NMDA injectionexpression profiles for (a) Tnfa, (b) Il1b and (c) Il6 mRNA levels in the retina after NMDA injection. All three cytokines were upregulated and peaked at D1 (n = 3, Tnfa, *p < .05 and **p < .01; Il1b, **p < .01; Il6, **p < .01, one-way ANOVA followed by Fisher's LSD test), associated with an increase in (d) Aif1 mRNA (n = 3-6, *p < 0.05 vs. control, MannWhitney U-test). MC (500 μM) dramatically suppressed (e) TNFα level, but did not suppress Il1b (f ) and only slightly suppressed Il6 (g) mRNAs (n = 3-6, Tnfa, **p < .01 vs. control, 
| RGC damages occur in temporal pattern similar to TNFα expression
Although Brn3a-based cell counting, degeneration of RGCs was started at D3, temporal profile of TNFα expression showed its peak at D1. Because proinflammatory cytokine-mediated neuronal death is usually caused by rapid action, we re-evaluated RGC damages by TUNEL. TUNEL-positive signals increased from 12 hr and peaked at D1 followed by rapid reduction at D3 and backed to the control level at D7 (Figure 8a,b) , highly correspondent to previous reports Kumada et al., 2004; Kwong et al., 2003; Kwong & Lam, 2000; Zhang et al., 2008) and the pattern for Tnfa expression. TUNEL signals were co-localized with pyknotic nuclei-like Brn3a signals (arrows in Figure 8c ) but not with large Brn3a signals (asterisks in Figure 8c ). We then further investigated microglial activation prior to RGC damages. Sholl analysis showed that microglia at 3 hr already retracted their processes (Figure 8d ,e). To reveal neurotoxic roles of activated microglia at very early stages, we next tested PLX effect on TUNEL signals at D1. PLX dramatically reduced the number of TUNEL-positive cells (Figure 8f ), indicating the central neurotoxic role of activated microglia at early stage.
| TNFα mediates RGC degeneration via TNF receptor type 1
To clarify whether the upregulated TNFα damages RGCs, we tested TNFα inhibitor SPD. SPD (1 μL of 20 mM) was injected simultaneously with NMDA (1 μL of 20 mM). NMDA-induced reduction in RGC number was partially, but significantly, recovered by SPD (Figure 9a,c) .
Interestingly, SPD did not show any inhibitory effect on microglial morphologies and cell number, but rather increased their cell number (Figure 9b,d) . To identify the receptor responsible for the neurotoxic effect of TNFα, we examined siRNAs for TNF receptor type 1 (siTNFR1) or type 2 (siTNFR2), and found that siTNFR1 restored RGC number (Figure 9a,c) . Similar to SPD, both siTNFR1 and siTNFR2
enhanced the increase in microglial number induced by NMDA (Figure 9d ). Knockdown efficiency of siTNFR1 was about 40%, whereas no effect was obtained with control siRNA (siCntl; Figure 9e ). Additionally, no neuroprotection was observed with siCntl ( Figure 9f ). Together, these data suggest that TNFα is a key cytotoxic factor of microglia-mediated RGC degeneration triggered by NMDA.
| DISCUSSION
In the present study, we demonstrated that microglial activation is essential for degeneration of RGCs induced by NMDA. The main findings showed that: (a) microglia became reactive in response to NMDA, which was accompanied with the damages or loss of Brn3a + RGCs;
(b) pharmacological inhibition and deletion of microglia and genetic ablation of microglia resulted in inhibition of the NMDA-induced RGC damages or degeneration; (c) production of TNFα in microglia and other cell types and activation of TNFR1 were the main mechanisms for microglia-mediated RGC degeneration. All these findings suggest that a phenotypic change in microglia is likely a key event for the degeneration of RGCs caused by excitotoxic insults.
Primary cultured retinal microglia showed no Ca 2+ responses to NMDA or no expression of Grin genes was observed in acutelyisolated retinal microglia, so their activation is likely triggered by other NMDA-activated cell types such as RGCs. Unlikely to hippocampal neurons, it has been reported that purified RGCs are resistant to NMDA (Ullian et al., 2004) , so non-cell-autonomous mechanism is likely to mediate RGC damages. In this study, we focused on microglia because many reports have shown that NMDA-evoked neuronal damages are enhanced in the presence of microglia (Kim & Ko, 1998; . If microglia mediate non-cellautonomous damages of RGCs, how do they cause microglial activation? NMDA receptors have been reported to activate pannexin-1 (Weilinger et al., 2016; Weilinger, Tang, & Thompson, 2012 ) and pannexin-1 is known to mediate ATP release (Chekeni et al., 2010) .
The NMDA-stimulated neurons release ATP and activate adjacent microglia (Dissing-Olesen et al., 2014; Eyo et al., 2014) . The released ATP is degraded into ADP and activates microglial P2Y 12 receptors, thereby causing process elongation toward neurons (Davalos et al., 2005; Haynes et al., 2006; Ohsawa et al., 2010) . Although the P2Y 12 receptor-mediated process extension of microglia is widely accepted,
we observed retracted processes of retinal microglia at 3 and 12 hr after NMDA injection. This discrepancy can be explained by adenosine or TNFα. The released ATP is soon degraded into adenosine, and activation of the adenosine A 2A receptor in microglia causes retraction of microglial processes (Orr, Orr, Li, Gross, & Traynelis, 2009 ). Alternatively, the P2Y 12 receptor-mediated process extension of microglia is reversed in the presence of TNFα (Orr et al., 2009) . Previous report and our current data showed that excitotoxic stimulation causes immediate upregulation of TNFa mRNA (Avignone, Ulmann, Levavasseur, Rassendren, & Audinat, 2008) and TNFα protein at as early as 3 hr especially in microglia. Thus, we consider that NMDA initially activates NMDA receptors of RGCs followed by signal transduction toward microglia via soluble factors such as ATP or possibly adenosine. However, further study is needed to clarify this.
We found that microglial activation occurs as early as 3 hr post-NMDA injection, earlier than the peak of TUNEL + RGCs (at D1) or the 
FIGURE 7 reduction in the number of Brn3a + RGCs (at D3). Similarly, microglial activation is also observed in the very early stage of the DBA2J glaucoma mouse model (Bosco, Steele, & Vetter, 2011; Howell et al., 2011) , it is conceivable that early phenotypic changes of microglia into a neurotoxic phenotype critically regulate damage of RGCs. In fact,
we observed that MC-mediated suppression of microglia significantly restored RGC damage, which was further confirmed by two alternative methods including pharmacological and genetic ablation of microglia. When compared with the neuroprotective effects of MC at D7, PLX and Iba1-DTA at D7 showed only partial effects on RGC damage, although they ablated almost all of the microglia (~90%). One possible explanation of this discrepancy is differences in their mechanisms:
PLX and genetic model have specific for microglia but MC is not.
Although MC is widely used as an inhibitor for microglia, we found that the neuroprotective effect by MC was observed in the absence of microglia, indicating direct neuroprotective effect by MC. Supporting our observation, MC has numerous effects on various cell types other than microglia (Moller et al., 2016) and has been reported to have direct neuroprotective action (Kraus et al., 2005; Schildknecht et al., 2011; Shimazawa et al., 2005) . In contrast to the data at D7, the protective effect by PLX at D1 was much stronger as approximately 80% reduction in TUNEL + cell number. This result strongly supports our idea of the central role of microglia in the neurotoxicity, however, mismatched with the result at D7 estimated by Brn3a + cell number. This point will be analyzed in the future study.
We found that mRNA for the proinflammatory cytokines Il-1b, Il-6, and TNFa were significantly increased at D1, and only TNFα was significantly suppressed by MC or PLX. Immunohistochemical data showed that TNFα at D1 was upregulated in mainly in RGCs and activated microglia. Notably, we found that almost all TNFα signals at 3 hr were localized in microglia, indicating that microglia are the initial source of TNFα and spread out to the other cell types afterward. A recent report has shown that aging-associated TNFα expression in hypothalamus is observed selectively in microglia at relatively younger ages but spreads into other cell types at older ages (Liddelow et al., 2017) or neuroprotective ones (Shinozaki, Shibata, et al., 2017b) . The microglial activation may be upstream signaling cascade of other cell types such as RGCs and
Müller cells, so MC and PLX blocked TNFα expression globally.
Because ATP can be released from NMDA-stimulated neurons, it is possible that purinergic receptors expressed in microglia contribute to the TNFα upregulation in microglia. Among purinergic receptor subtypes, the P2X 7 receptor has been reported to highly expressed in microglia and mediate TNFα production from microglia (Suzuki et al., 2004) . Consistent with this idea, we found a significant increase in retinal P2rx7 mRNA at D1 (more than five fold, data not shown) and an antagonist for P2X 7 receptor has been shown to protect RGCs from NMDA (Sakamoto et al., 2015) and block the up-regulation of TNFα (Sugiyama et al., 2013) . Thus, RGC-derived ATP may activate microglial P2X 7 receptors, thereby triggering TNFα production.
Our data showed that one candidate for neurotoxic molecules induced by NMDA was TNFα. Recombinant TNFα is enough to cause degeneration of RGCs (Kitaoka et al., 2006; Nakazawa et al., 2006) and the TNFα-mediated RGC damages have been shown in ocular hypertension (Fontaine et al., 2002; Nakazawa et al., 2006; and optic nerve crush (Tezel, Yang, Yang, & Wax, 2004) .
TNFα may also be related in the human ocular diseases: TNFα levels are elevated in the aqueous humor of POAG patients (Balaiya et al., 2011; Sawada et al., 2010) , and a polymorphism of the Tnfα gene is a risk factor for POAG (Funayama et al., 2004; Hollegaard & Bidwell, 2006) . Previous immunohistochemical analyses have demonstrated that retinal TNFα levels are elevated in glaucoma patients, especially near the optic nerve head (Yan, Tezel, Wax, & Edward, 2000; Yuan & Neufeld, 2000) . Some reports demonstrated that neuroprotective action of TNFα in the optic nerve transection model (Diem, Meyer, Weishaupt, & Bahr, 2001; Mac Nair, Fernandes, Schlamp, Libby, & Nickells, 2014) . One possible mechanism for the controversial study can be explained by the receptor for TNFα: TNFR1 and TNFR2.
TNFR1 was found to be crucial for RGC degeneration in our experimental conditions. This finding is consistent with the upregulation of TNFR1 in retina of glaucoma patients Yan et al., 2000; Yuan & Neufeld, 2000) . TNFR1 signals have been observed in RGCs Yuan & Neufeld, 2000) and GFAP-positive cells in glaucoma patients (Yuan & Neufeld, 2000) . TNFα binds to two types of receptors: TNFR1 and TNFR2. TNFR1 transduces its signal to the adaptor protein TNF receptor-associated death domain. This causes caspase-8 activation and apoptosis (Weiss et al., 1998) . TNFR2 recruits TNF receptor-associated factor 2 (TRAF2) and cellular inhibitor of apoptosis protein-1 and -2 (cIAP-1 and cIAP-2) resulting in an antiapoptotic effect (Mukhopadhyay, Suttles, Stout, & Aggarwal, and siRNA for Tnfr1 (siTNFR1) showed a partial neuroprotective effect (n = 3-7, **p < .01 vs. control and ## p < .01 vs. NMDA, one-way ANOVA followed by Fisher's LSD test], whereas no protective effect was observed with siRNA for Tnfr2 (siTNFR2) at D7. (b,d) effect of SPD, siTNFR1 and siTNFR2 on microglia at D7. SPD, siTNFR1 or siTNFR2 increased the number of reactive microglia induced by NMDA (n = 3-7, **p < .01 vs. control and ## p < .01 vs. NMDA, one-way ANOVA followed by Fisher's LSD test). (e) Knockdown efficiency at D1. About 40% reduction in Tnfr1 mRNA level was obtained by the siTNFR1 (n = 3-7, **p < .01 vs. NMDA, one-way ANOVA followed by Fisher's LSD test). No effect on Tnfr1 mRNA level was observed by control siRNA (siCntl). (f ) No neuroprotection was observed by siCntl at D7 (n = 3-7, p = .052, NMDA vs. NMDA/siCntl, unpaired t test) [Color figure can be viewed at wileyonlinelibrary.com]
